Following Institutional Review Board approval, we performed a retrospective (1988-2008) multi-institutional study from 3 medical centers in the United States involving cases of HIV-positive ...

Colorectal adenocarcinoma incidence is decreasing overall but increasing among individuals aged 15 to 34 years, with an APC of 1.75. Pancreatic adenocarcinoma incidence is rising across all age groups ...

From 2000 to 2021, the incidence of pancreatic adenocarcinoma rose among all age groups in the United States, with the highest increase in those aged 15-34 years. During the same period, the overall ...

Micrograph of colorectal adenocarcinoma. Image by Mikael Häggström, M.D. Own work, CC0 Micrograph of colorectal adenocarcinoma. Image by Mikael Häggström, M.D. Own work, CC0 Colorectal cancer is known ...

Korean Society of Coloproctology trial of consolidation chemotherapy for locally advanced mid or low rectal cancer after neoadjuvant concurrent chemoradiotherapy: KONCLUDE multicenter radomized trial.

Colorectal cancer is a high disease burden cancer and is the second leading cause of cancer deaths worldwide. The first-line treatment option is surgical resection of cancerous tissue. However, the ...

Please provide your email address to receive an email when new articles are posted on . Rates of pancreatic adenocarcinoma increased significantly among younger individuals than older ones. Colorectal ...

Panitumumab retreatment followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA (ctDNA): Results ...

Data presented at ESMO 2025 show INCA33890, a TGFβR2×PD-1 bispecific antibody, has the potential to be an effective treatment in microsatellite stable (MSS) colorectal cancer Planned initiation of ...